Auspex Pharmaceuticals
- Company typePrivate
- Founded2001
- HeadquartersLa Jolla, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Auspex Pharmaceuticals firmographics
Firmographics- Name
- Auspex Pharmaceuticals
- Legal name
- Auspex Pharmaceuticals
- Website
- https://auspexpharma.com
- Company type
- Private
- Founded year
- 2001
- Operating status
- Acquired
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Auspex Pharmaceuticals industry classification
Industry- Product category
- Neurology Biopharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)
- akta.pro secondary industry
- Therapeutic Peptides & Protein/Peptide Biologics (HLAAAAAH)
Keywords
Where Auspex Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- La Jolla
- HQ country
- United States
- HQ region
- North America
Markets served
Auspex Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Auspex Pharmaceuticals product offering
Product offeringCore offering
Auspex Pharmaceuticals developed deuterated small-molecule and peptide therapeutics for central nervous system disorders, with a primary focus on deutetrabenazine (SD-809) for the treatment of chorea associated with Huntington's disease and tardive dyskinesia. The company leveraged proprietary deuteration chemistry to improve pharmacokinetic properties, dosing convenience, and tolerability of approved drug scaffolds.
Differentiator
Problem solved
Functional benefit
Products and services
- Deutetrabenazine (SD-809 / Austedo)
Companies that use Auspex Pharmaceuticals
Customer profileSegments1 record
Ideal customer profiles1 record
Auspex Pharmaceuticals technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Auspex Pharmaceuticals partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Teva PharmaceuticalscoreTeva Pharmaceuticals acquired Auspex Pharmaceuticals for a Huntington's disease candidate. This acquisition represents Teva's strategic move to expand its innovative medicine portfolio in neuroscience and immunology therapeutic areas. The acquisition brought Auspex's peptide therapeutics pipeline under Teva's ownership, strengthening Teva's position in neurological disorders treatment development.
Recent moves5 records
Auspex Pharmaceuticals competitors and assessment
Company assessmentBroad incumbents
- Lundbeck: Lundbeck markets tetrabenazine (Xenazine), the established VMAT2 inhibitor for Huntington's disease chorea, making it the closest direct incumbent competitor to Auspex's lead deutetrabenazine candidate in the same CNS indication.
- Teva Pharmaceuticals: Teva acquired Auspex and is a global biopharma leader with a stated focus on neuroscience, providing a direct comparison point for Auspex's CNS pipeline positioning within a larger strategic acquirer.
- Neurocrine Biosciences: Neurocrine is a larger CNS-focused biopharma with a commercial neurology portfolio, comparable to Auspex in therapeutic area focus but operating at significantly greater scale and with broader CNS pipeline.
Direct peers
- Prilenia Therapeutics: Prilenia is a clinical-stage company developing pridopidine for Huntington's disease, directly competing in the same neurological indication that Auspex targeted, with comparable patient population and regulatory pathway.
- Acadia Pharmaceuticals: Acadia is a CNS-focused biopharma commercializing therapies for neurological and psychiatric disorders, directly comparable to Auspex in therapeutic area focus and patient-centric CNS drug development.
- Ionis Pharmaceuticals: Ionis developed tominersen (an antisense oligonucleotide) for Huntington's disease in partnership with Roche, directly overlapping with Auspex's CNS/neurology therapeutic focus and patient population.
- Sage Therapeutics: Sage develops CNS therapeutics for depression and neurology, overlapping with Auspex's deuteration-based approach to CNS drug development and its stated focus on depressive disorders.
- Wave Life Sciences: Wave develops stereopure oligonucleotide therapies for neurological diseases including Huntington's disease, sharing Auspex's focus on CNS genetic/neurological disorders with a differentiated chemistry-based platform.
Emerging players
- PTC Therapeutics: PTC develops small-molecule therapies targeting neurological and rare diseases, with overlapping CNS therapeutic interests comparable to Auspex's small-molecule/deuteration drug development approach.
- Voyager Therapeutics: Voyager develops gene therapies for neurological diseases including Huntington's, sharing Auspex's CNS focus and rare neurological disease orientation, though with a different therapeutic modality.
Market position
Strengths3 records
Weaknesses3 records
Competitive moat3 records
Key risks4 records
Key highlights5 records
Customer concentration
Auspex Pharmaceuticals social profiles
Digital presenceAuspex Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Auspex Pharmaceuticals leadership team
Management profileNumber of profiles
Auspex Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds10 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Auspex Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Auspex Pharmaceuticals
What does Auspex Pharmaceuticals do?
Auspex Pharmaceuticals developed deuterated small-molecule and peptide therapeutics for central nervous system disorders, with a primary focus on deutetrabenazine (SD-809) for the treatment of chorea associated with Huntington's disease and tardive dyskinesia. The company leveraged proprietary deuteration chemistry to improve pharmacokinetic properties, dosing convenience, and tolerability of approved drug scaffolds.
Is Auspex Pharmaceuticals a public or private company?
Auspex Pharmaceuticals is a private company. It is classified as corporate owned and is currently acquired.
When was Auspex Pharmaceuticals founded?
Auspex Pharmaceuticals was founded in 2001. It employs 11 to 50 people.
Where is Auspex Pharmaceuticals based?
Auspex Pharmaceuticals is headquartered in La Jolla, United States, in the North America region.
Who are Auspex Pharmaceuticals's main competitors?
Broad incumbents on record are Lundbeck, Teva Pharmaceuticals and Neurocrine Biosciences. Direct peers are Prilenia Therapeutics, Acadia Pharmaceuticals, Ionis Pharmaceuticals, Sage Therapeutics and Wave Life Sciences. Emerging players are PTC Therapeutics and Voyager Therapeutics.
Does Auspex Pharmaceuticals have an API?
No public API is recorded for Auspex Pharmaceuticals.
What industry is Auspex Pharmaceuticals in?
Auspex Pharmaceuticals's product category is Neurology Biopharmaceuticals. Its primary akta.pro industry code is HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals, with a secondary code of HLAAAAAH, Therapeutic Peptides & Protein/Peptide Biologics. Its NAICS code is 325414 and its SIC code is 2834.